Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety

BACKGROUND: Lisinopril and losartan manufacturer labels recommend twice-daily dosing (BID) if once-daily (QDay) is insufficient to lower blood pressure (BP). METHODS AND RESULTS: Retrospective cohort study of patients taking QDay lisinopril and losartan who experienced a dose-doubling (index date)....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:PLoS One
Hoofdauteurs: Derington, Catherine G., King, Jordan B., Delate, Thomas, Botts, Sheila R., Kroehl, Miranda, Kao, David P., Trinkley, Katy E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Public Library of Science 2020
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7714357/
https://ncbi.nlm.nih.gov/pubmed/33270787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0243371
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items